JOHNSON & JOHNSON — Director's Dealing 2023

Feb 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2023-02-10

Reporting Person: Taubert Jennifer L (EVP, WW Chair, Pharmaceuticals)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-10	Common Stock	M	3570.0000	$0.0000	Acquired	130026.0010	Direct
2023-02-10	Common Stock	F	1289.0000	$162.0800	Disposed	128737.0010	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-10	Restricted Share Units	$	M	3570.0000	Disposed		Common Stock (3570.0000)	Direct

Footnotes

F1: Restricted Share Units awarded under Long-Term Incentive Plan on February 10, 2020 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting.

F2: Shares withheld for payment of taxes upon vesting of Restricted Share Units.